Candesant Biomedical, a private medical device company, has announced the completion of a Series B financing round, securing a total of £35m to further the commercialisation of Brella, the first and only 3-Minute SweatControl Patch cleared by the FDA.
The company is dedicated to developing and commercialising non-invasive treatments for hyperhidrosis, also known as excessive sweating.
The funding round was led by KCK MedTech, a venture capital firm specialising in medical technologies, in collaboration with other investors such as Polaris Partners, Astia Fund, and Correlation Ventures.
Candesant founder and CEO Niquette Hunt said: “We are proud to secure this financing supporting the ongoing commercialisation efforts of Brella and its national launch in 2024.
“With this investment, we look forward to advancing our Brella Early Experience Program later this year with select practices within the U.S. and achieving our mission to help millions of Americans affected physically, emotionally, and financially by excessive underarm sweating.”
Brella received clearance from the US Food and Drug Administration (FDA) in April this year for the management of excessive underarm sweating in adults with primary axillary hyperhidrosis.
It offers a novel in-office method for controlling sweat that is quick, non-invasive, free from needles and aluminium, comfortable, and cost-effective. Its effects typically last for a duration of three to four months.
KCK MedTech senior managing director Karen Long said: “The market is long overdue for a convenient, efficacious, and affordable option for excessive sweating, and we believe Brella has the potential to set a new standard of care in hyperhidrosis management for both providers and patients.
“We are pleased to be supporting Candesant Biomedical as they prepare to launch this exciting new product, Brella.”
